

Eansor Norman David
Form 4
August 09, 2018

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Eansor Norman David

2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [TECH]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)

____ Director _____ 10% Owner
____ Officer (give title below) _____ Other (specify below)

8100 SOUTHPARK WAY, A-8

08/07/2018

SVP - Novus Biologicals

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
X Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

LITTLETON, CO 80120

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|--|
| | | | | (A) or (D) Price | | | |
| Common Stock | 08/07/2018 | | M | 1,199 A \$ 0 | 3,465 | D | |
| Common Stock | 08/07/2018 | | F | 348 D \$ 180.14 | 3,117 | D | |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Edgar Filing: Eansor Norman David - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | Amount or Number of Shares |
|--|--|--------------------------------------|--|--------------------------------|---|--|-----------------|---|----------------------------|
| | | | | Code | V (A) (D) | Date Exercisable | Expiration Date | Title | |
| Restricted Stock Units | (1) | 08/07/2018 | | M | | 1,199 | (2) (2) | Common Stock | 1,199 |
| Restricted Stock Units | (1) | 08/07/2018 | | D | | 301 | (2) (2) | Common Stock | 301 |
| Stock Options (Right to buy) | \$ 108.49 | 08/07/2018 | | D | | 1,881 | (3) 08/07/2022 | Common Stock | 1,881 |
| Restricted Stock Units | (1) | 08/08/2018 | | A | | 2,537 | (4) (4) | Common Stock | 2,537 |
| Stock Options (Right to buy) | \$ 177.32 | 08/08/2018 | | A | | 18,066 | (5) 08/08/2025 | Common Stock | 18,066 |
| Stock Options (Right to buy) | \$ 177.32 | 08/08/2018 | | A | | 13,550 | (4) 08/08/2025 | Common Stock | 13,550 |
| Restricted Stock Units | (1) | | | | | | (6) (6) | Common Stock | 2,280 |
| Restricted Stock Units | (1) | | | | | | (7) (7) | Common Stock | 2,170 |
| Stock Option (Right to Buy) | \$ 108.49 | | | | | | (8) 08/07/2022 | Common Stock | 12,500 |
| Stock Option (Right to | \$ 94.35 | | | | | | (9) 08/12/2021 | Common Stock | 15,000 |

Buy)

Stock

Options
(Right to
buy)

\$ 125.05

(7)

08/09/2024

Common
Stock

11,9

Stock

Options
(Right to
buy)

\$ 125.05

(10)

08/09/2024

Common
Stock

15,9

Stock

Options
(Right to
buy)

\$ 106.59

(11)

08/18/2023

Common
Stock

18,8

Stock

Options
(Right to
buy)

\$ 106.59

(6)

08/18/2023

Common
Stock

14,1

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|---|---------------|-----------|-------------------------|-------|
| | Director | 10% Owner | Officer | Other |
| Eansor Norman David 8100 SOUTHPARK WAY, A-8 LITTLETON, CO 80120 | | | SVP - Novus Biologicals | |

Signatures

/s/ Brenda S. Furlow, attorney in fact for N. David Eansor pursuant to Power of Attorney
previously filed

08/09/2018

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- (2) On 8/7/2018, the Board of Directors authorized discretionary vesting for 1,199 performance RSUs. The remainder of the performance RSUs were forfeited.
- (3) On 8/7/2018, the Board of Directors authorized discretionary vesting for 7,494 performance options. The remainder of the performance options were forfeited.
- (4) Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- (5) Vests 4,517 shares each on 8/8/2019, 8/8/2020 and 4,516 shares each on 8/8/2021, 8/8/2022.
- (6) Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- (7)

Edgar Filing: Eansor Norman David - Form 4

Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

- (8) 3,125 shares vest on each of 8/7/16, 8/7/17, 8/7/18 and 8/7/19.
- (9) 3,750 shares vest on each of 8/12/15, 8/12/16, 8/12/17 and 8/12/18.
- (10) Vest 3,994 shares on each 8/9/2018, 8/9/2019, 8/9/2020, 8/9/2021
- (11) Vests 4,705 shares on 8/18/17, 8/18/18, and 8/18/19 and 4,704 shares on 8/18/20.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.